Goodwin advised Jefferies LLC as the placement agent in an approximately $40 million registered direct offering of ImmunityBio, Inc.’s common stock and accompanying warrants. ImmunityBio’s common stock is listed on the Nasdaq Global Select Market under the symbol “IBRX.”
ImmunityBio is a clinical-stage biotechnology company developing next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases.
The deal team consisted of Bryan Quinn, Griffin Drake, and Harper Vincent (Corporate); Ora Grinberg and Chris Zhao (Tax); Michael Shuster (IP); and Brad Weber (Opinions).
For additional details on the transaction, please read the press release.